Quantum Biopharma (QNTM) Long-Term Deferred Tax (2021 - 2025)

Quantum Biopharma's Long-Term Deferred Tax history runs 5 years deep, the most recent figure standing at $1.2 million for Q4 2025.

• In Q4 2025, Long-Term Deferred Tax fell 98.86% year-over-year to $1.2 million; the TTM figure through Dec 2025 stood at $1.2 million (down 98.86% YoY), while the FY2025 annual figure was $1.2 million, down 98.86% from the prior year.
• Long-Term Deferred Tax came in at $1.2 million for Q4 2025 at Quantum Biopharma, down from $109.1 million in the prior quarter.
• In the past five years, Long-Term Deferred Tax ranged from a high of $109.1 million in Q4 2024 to a low of $1.2 million in Q4 2025.
• A 5-year average of $76.0 million and a median of $90.4 million in 2022 frame the typical range for Long-Term Deferred Tax.
• Across the five-year window, Long-Term Deferred Tax increased 16.94% in 2022 and tumbled 98.86% in 2025, its largest moves.
• Quantum Biopharma's Long-Term Deferred Tax stood at $77.3 million in 2021, then rose by 16.94% to $90.4 million in 2022, then advanced by 12.7% to $101.9 million in 2023, then advanced by 7.03% to $109.1 million in 2024, then sank by 98.86% to $1.2 million in 2025.
• According to Business Quant data, Long-Term Deferred Tax over the past three periods registered $1.2 million, $109.1 million, and $101.9 million for Q4 2025, Q4 2024, and Q4 2023 respectively.

Peer Comparison